Mesenchymal stem cells derived from Wharton's Jelly in cardiopulmonary injury and systemic neuroimmunomodulation in sepsis

Abstract

Sepsis is a disease related to the presence of infection with a systemic inflammatory response, its pathophysiology involves a complex network of cytokines and inflammatory mediators that cause injury to various tissues. Currently there are many attempts to reduce mortality, although there is not specific strategy for treating the disease. In recent years, stem cells have received great interest in the treatment of inflammatory and degenerative diseases; in the last decade many studies have shown that mesenchymal stem cells (MSCs) have immunosuppressive and immunomodulatory properties, and that they can protect the inflammatory effect during endotoxemia. It is currently already being used MSC as a last resource in a number of critical illnesses, although there are still some controversies in the results. About the treatment of sepsis with stem cells, first, is necessary the expansion of pre-clinical studies before of its application in clinical practice. With the knowledge of the properties of CTM and its viability in interspecies therapy, our aim is to study the effect of mesenchymal stem cells from human Wharton jelly in an experimental sepsis model "rats" (ligation and puncture Ceco, LPC). The animals will be randomized into three groups: LPC (group of sepsis induction), LPC + CTM (group with induction of more sepsis treatment with stem cells) and SHAM (control group). The groups will submitted to cardiac, pulmonary, immune and autonomic evaluation, beyond the mechanisms involved as result of treatment; finally, the data obtained will be evaluate to analysis of variance, followed by Newman-Keuls test. The degree of significance for statistical analysis will be p<0.05.